Your browser doesn't support javascript.
loading
Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
Tofte, Nete; Theilade, Simone; Winther, Signe A; Birkelund, Sørine; Goetze, Jens P; Hansen, Tine W; Rossing, Peter.
Afiliação
  • Tofte N; Steno Diabetes Center Copenhagen, Gentofte, Denmark nete.tofte@regionh.dk.
  • Theilade S; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Winther SA; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Birkelund S; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Goetze JP; Department of Technology, Faculty of Health, University College Copenhagen, Copenhagen, Denmark.
  • Hansen TW; Department of Clinical Biochemistry, Rigshospitalet, Denmark.
  • Rossing P; University of Copenhagen, Copenhagen, Denmark.
Diabetes Care ; 44(2): 595-603, 2021 02.
Article em En | MEDLINE | ID: mdl-33323477
ABSTRACT

OBJECTIVE:

Few studies have compared midregional proatrial natriuretic peptide (MR-proANP) and N-terminal probrain natriuretic peptide (NT-proBNP). We compared their value as risk markers for all-cause mortality and cardiovascular (CV) and renal complications in individuals with type 1 diabetes. RESEARCH DESIGN AND

METHODS:

MR-proANP and NT-proBNP were measured in 664 individuals. Hazard ratios (HRs) were assessed per doubling of NT-proBNP or MR-proANP for risk of a composite of ischemic events, heart failure (HF), a combined renal end point of end-stage kidney disease (ESKD), decline in estimated glomerular filtration rate (eGFR) ≥30%, and all-cause mortality or individual end points. Adjustments included CV risk factors and addition of MR-proANP or NT-proBNP.

RESULTS:

Median follow-up was 5.1-6.2 years. MR-proANP was associated with higher risk of all-cause mortality (n = 57; HR 1.7, 95% CI 1.1-2.7), combined CV end point (n = 94; 1.6, 1.1-2.2), HF (n = 27; 2.8, 1.5-5.2), combined renal end point (n = 123; 1.6, 1.2-2.1), and ESKD (n = 21; 3.1, 1.2-7.8) independent of CV risk factors (P ≤ 0.02). After addition of NT-proBNP, significance for all end points was lost. A doubling of NT-proBNP was associated with higher risk of all-cause mortality (HR 1.5, 95% CI 1.2-1.8), the combined CV end point (1.3, 1.1-1.5), HF (1.7, 1.3-2.1), and the combined renal end point (1.3, 1.1-1.4) independent of CV risk factors (model 2 [P < 0.001]) and MR-proANP (model 3 [P ≤ 0.03]). There was no association with decline in eGFR ≥30% (n = 93).

CONCLUSIONS:

Higher NT-proBNP was independently associated with all-cause mortality, CV disease, HF, and the combined renal end point. MR-proANP was associated with all end points but decline in eGFR, although not independent of NT-proBNP. MR-proANP may contribute to the predictive value of NT-proBNP for risk stratification in type 1 diabetes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 1 / Insuficiência Cardíaca Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 1 / Insuficiência Cardíaca Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article